重组人促红细胞生成素治疗肾性贫血的临床应用分析

目的了解重组人促红细胞生成素（rhEPO）治疗肾性贫血的临床效果，为临床合理用药提供依据。方法对59例慢性肾性贫血患者采用皮下注射rhEPO治疗，每周三次，连续8周，同时补充右旋糖酐铁，叶酸和维生素B12，疗程结束后判定临床疗效，对比分析治疗前后Hb、网织红细胞（Rc）、红细胞压积（HCT）以及外周血异型红细胞百分率。结果显效23例，有效27例，无效9例，总有效率为84．7％（50／59）；发生不良反应11例，其中血压增高6例，头痛3例，注射部位疼痛2例，经对症处理后好转，未影响治疗。治疗后HCT、Hb、Rc均明显升高，异型红细胞明显减少，治疗前后比较差异有统计学意义仍〈0．05）。结论rhEPO治疗肾性贫血，安全、有效，不良反应少，值得临床推广应用。

Recombinant human erythropoietin treatment of renal anemia Clinical application of

Objective Understanding of recombinant human erythropoietin （rhEPO） treatment of renal anemia clinical effect, provide the basis for the clinical use of drugs.Methods 59 cases of patients with chronic renal anemia treatment with rhEPO subcutaneously three times a week for 8 weeks and iron dextran, folic acid and vitamin B12, after treatment to determine clinical efficacy, compared before and after treatment Hb, reticuloeyte Red blood cell （Rc）, hematocrit （HCT） and the percentage of peripheral blood shaped red blood cells.. Results 23 cases markedly effective in 27 cases, 9 cases, total effective rate was 84.7% （50/59）; 11 cases of adverse reactions, including increased blood pressure in 6 cases, 3 cases of headache, injection site pain in 2 cases after symptomatic treatment improved, did not affect treatment. After treatment, HCT, Hb, Rc increased significantly, shaped red blood ceils decreased significantly after treatment was significantly （P 〈0.05）.Conclusions rhEPO treatment of renal anemia, safe, effective, less adverse reaction worthy of clinical application.